ReShape Operating Margin from 2010 to 2025
| RSLS Stock | USD 0.52 0.13 20.00% |
Check ReShape Lifesciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ReShape Lifesciences' main balance sheet or income statement drivers, such as Interest Expense of 22.2 K, Other Operating Expenses of 26.5 M or Total Operating Expenses of 24.6 M, as well as many indicators such as Price To Sales Ratio of 0.19, Dividend Yield of 0.0 or PTB Ratio of 0.24. ReShape financial statements analysis is a perfect complement when working with ReShape Lifesciences Valuation or Volatility modules.
ReShape | Operating Margin |
Latest ReShape Lifesciences' Operating Margin Growth Pattern
Below is the plot of the Operating Profit Margin of ReShape Lifesciences over the last few years. It is ReShape Lifesciences' Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ReShape Lifesciences' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (1.05) % | 10 Years Trend |
|
Operating Profit Margin |
| Timeline |
ReShape Operating Margin Regression Statistics
| Arithmetic Mean | (39.46) | |
| Geometric Mean | 12.47 | |
| Coefficient Of Variation | (100.43) | |
| Mean Deviation | 36.30 | |
| Median | (24.40) | |
| Standard Deviation | 39.64 | |
| Sample Variance | 1,571 | |
| Range | 94.382 | |
| R-Value | 0.84 | |
| Mean Square Error | 491.37 | |
| R-Squared | 0.71 | |
| Significance | 0.000044 | |
| Slope | 7.01 | |
| Total Sum of Squares | 23,565 |
ReShape Operating Margin History
About ReShape Lifesciences Financial Statements
ReShape Lifesciences shareholders use historical fundamental indicators, such as Operating Margin, to determine how well the company is positioned to perform in the future. Although ReShape Lifesciences investors may analyze each financial statement separately, they are all interrelated. The changes in ReShape Lifesciences' assets and liabilities, for example, are also reflected in the revenues and expenses on on ReShape Lifesciences' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California. Reshape Lifesciences operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 47 people.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for ReShape Stock Analysis
When running ReShape Lifesciences' price analysis, check to measure ReShape Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ReShape Lifesciences is operating at the current time. Most of ReShape Lifesciences' value examination focuses on studying past and present price action to predict the probability of ReShape Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ReShape Lifesciences' price. Additionally, you may evaluate how the addition of ReShape Lifesciences to your portfolios can decrease your overall portfolio volatility.